Copanlisib

Bayer will work with the FDA toward voluntary withdrawal of its follicular lymphoma treatment copanlisib from the U.S. market, according to a company-issued press release.

The addition of copanlisib to rituximab extended PFS among patients with relapsed follicular lymphoma or marginal zone lymphoma, according to a subset analysis of the randomized phase 3 CHRONOS-3 trial.

The addition of copanlisib to rituximab increased response rates and significantly extended PFS among patients with relapsed indolent non-Hodgkin lymphoma, according to study results.

The addition of copanlisib to rituximab extended PFS among patients with relapsed indolent non-Hodgkin lymphoma who received prior rituximab-containing therapy, according to topline data released by the agent’s manufacturer.